SCHEMBL2229135

SCHEMBL2229135

O=C(O)c1ccc2cc3c(nc2c1)CCCC3

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
GRM1 Q13255 3/20 0.48
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
TP53 P04637 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
KDM4E B2RXH2 3/20 0.42
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
CASP3 P42574 1/20 0.41
KLF5 Q13887 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22703708 0.88 GRM1 (0.61) ALDH1A1GRM1MAPTSMN1; SMN2TP53
SCHEMBL2228761 0.86 GRM1 (0.47) ALDH1A1GRM1MAPTSMN1; SMN2TP53
SCHEMBL30098818 0.86 GRM1 (0.47) ALDH1A1GRM1MAPTSMN1; SMN2TP53
SCHEMBL28031996 0.82 GRM1 (0.50) ALDH1A1GRM1MAPTSMN1; SMN2KDM4E
SCHEMBL14565647 0.80 TDP1 (0.61) ALDH1A1MAPTSMN1; SMN2RXFP1TDP1
Bicarbonate SCHEMBL4200785 0.78 ALDH1A1 (0.49) ALDH1A1GRM1MAPTSMN1; SMN2TP53
SCHEMBL28032001 0.75 MAPT (0.41) ALDH1A1GRM1MAPTSMN1; SMN2TP53
SCHEMBL27878403 0.74 ALDH1A1 (0.43) ALDH1A1GRM1MAPTSMN1; SMN2TP53
SCHEMBL22703612 0.74 GRM1 (0.41) ALDH1A1GRM1MAPTSMN1; SMN2TP53
SCHEMBL22690048 0.74 GRM1 (0.60) ALDH1A1GRM1MAPTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
CN-102781919-B As the amido acridine derivatives of the selective depressant of ubiquitin-specific protease 7 HYBRIGENICS S.A. (FR) 2016-01-20 CN disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
EP-2523938-B1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2014-09-03 EP disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
EP-2523938-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Hybrigenics S.A. (FR) 2012-11-21 EP disclosed
CN-102781919-A Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA 2012-11-14 CN disclosed
WO-2011086178-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 ALDH1A1 3216/4885GRM1 3878/4885MAPT 704/4885
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 ALDH1A1 3216/4885GRM1 3878/4885MAPT 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.